Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Ribociclib). Same strength and form. Confirm the switch with your doctor or pharmacist.
Indications & Uses
Riclib 200 Tablet is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The recommended dose of Ribociclib is 600 mg taken orally, once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. Ribociclib can be taken with or without food.
Side Effects
Most common adverse effects (incidence >20%) are neutropenia, nausea, infections, fatigue, diarrhea, leukopenia, vomiting, alopecia, headache, constipation, rash and cough.
Cautions & Contraindications
Warnings & Precautions
Interstitial Lung Disease/Pneumonitis: Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with Kisqali and other CDK4/6 inhibitors. Monitor patients for pulmonary symptoms indicative of ILD pneumonitis which may include hypoxia, cough and dyspnea.Severe Cutaneous Adverse Reactions: Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) can occur.QT Interval Prolongation: Kisqali has been shown to prolong the QT interval. Based on the observed QT prolongation during treatment Kisqali may require dose interruption, reduction or discontinuation. Monitor serum electrolytes (including potassium, calcium, phosphorous and magnesium) prior to the initiation of treatment at the beginning of the first 6 cycles and as clinically indicated.Increased QT Prolongation with Concomitant Use of Tamoxifen: Kisqali is not indicated for concomitant use with tamoxifen.Hepatobiliary Toxicity: Perform liver function tests (LFTs) before initiating therapy with Kisqali. Monitor LFTs every 2 weeks for first 2 cycles at the beginning of each subsequent 4 cycles and as clinically indicated. Based on the severity of the transaminase elevations, Kisqali may require dose interruption, reduction or discontinuation.Neutropenia: Perform complete blood count (CBC) before initiating therapy with Kisqali. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles and as clinically indicated. Based on the severity of the neutropenia, Kisqali may require dose interruption, reduction or discontinuation.Embryo-Fetal Toxicity: Based on findings from animal studies and the mechanism of action, Kisqali can cause fetal harm when administered to a pregnant woman. Advise women of reproductive potential to use effective contraception during therapy with Kisqali and for at least 3 weeks after the last dose.
Contraindications
Ribociclib is contraindicated in patients with known hypersensitivity to this product or any of its components.